替米沙坦联合心脑康胶囊治疗糖尿病肾病

目的观察替米沙坦联合心脑康胶囊治疗糖尿病肾病(DN)的临床疗效。方法选择DN患者60例,随机分成治疗组和对照组,两组均可采用胰岛素和口服降糖药降血糖,对照组使用替米沙坦,治疗组予心脑康胶囊联合替米沙坦,疗程为3个月。治疗前后分别测血压(SBP/DBP)、空腹血糖(FBG)、糖化血红蛋白(HbAlc)、尿素氮(BUN)、血肌酐(SCr)、肾小球滤过率(eGFR)、尿β2微球蛋白(β2-MG)。结果两组SBP、DBP、FBG、SCr、eGFR、尿β2微球蛋白(β2-MG)、HbAlc治疗后与治疗前比较有显著意义(P0.05);治疗组治疗后BUN、SCr、HbAlc、尿β2微球蛋白(β2-MG)、eGFR与对照组治疗后比较有统计学意义(P0.05)。结论替米沙坦联合心脑康胶囊治疗DN,在减少尿蛋白、改善肾功能方面明显优于对照组,提示两药合用可有效控制和延缓DN病情的发展。

the Therapeutic Effect of Treating Diabetic Nephropathy(DN) by Xinnaokang capsules Combined with Telmisartan

Objective：To observe the therapeutic effect of treating diabetic nephropathy （DN） using Xinnaokang capsule combined with Telmisartan. Methods：60 patients of DN were randomly divided into two groups, treatment group and control group. The control group was given Telmisartan the treating group was given Xinnaokang capsule combined with Telmisartan, the course is 3 months. SBP/DBP,FBG, BUN, SCr,eGFR ,urine 32 tiny globulin （132-MG） ,HbAlc were tested before and after treatment. Results：There was significant difference in SBP ,DBP,BUN ,SCr,eGFR ,urine 132 tiny globulin（132-MG） ,FPG,HbAlc level before and after treatment in two groups （P 〈 0.05 ）. The data of BUN ,SCr,eGFR,urine 132 tiny globulin（132-MG） ,HbAlc in treatment group was better than the control group. Conclusions：Treating diabetic nephropathy using Xinnaokang capsule combined with Telmisartan has a better effect in reducing the urine protein and improving renal function than control group, hint combination medicine can effectively control and defer the development of the condition of DN.